|
| Press Releases |
|
 |
|
| Tuesday, April 16, 2024 |
|
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
| SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, August 14, 2023 |
|
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, June 12, 2023 |
|
|
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, May 22, 2023 |
|
|
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, December 19, 2022 |
|
|
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 4, 2022 |
|
|
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, August 24, 2022 |
|
|
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, July 8, 2022 |
|
|
SinoMab Received the Highest Subsidy from HKSTP |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
| Tuesday, June 21, 2022 |
|
|
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
foundit Insights Tracker Reveals 20% Surge in Hiring Activity in the Philippines: A Beacon for Southeast Asia
Nov 28, 2024 06:00 HKT/SGT
|
|
|
LANGHAM BEAUTY Green Vitality 
Nov 27, 2024 22:05 HKT/SGT
|
|
|
GMG's THERMAL-XR(R) Awarded Product of the Year at the AIRAH 2024 Awards
Nov 27, 2024 21:59 HKT/SGT
|
|
|
EdgePoint Infrastructure Inks Strategic Partnership with CelcomDigi to expand connectivity in Malaysia at TowerXchange Meet Up Asia 2024
Nov 27, 2024 21:30 HKT/SGT
|
|
|
Step Into the World of Jean-Michel Basquiat
Nov 27, 2024 20:00 HKT/SGT
|
|
|
Expert Systems Announces FY25 Interim Results
Nov 27, 2024 19:50 HKT/SGT
|
|
|
Kingworld-Longde Life and Health Industrial Park Grand Opening
Nov 27, 2024 19:40 HKT/SGT
|
|
|
Swire Coca-Cola Hong Kong Leverages SAP S/4HANA and SAP Services to Drive Digital Transformation
Nov 27, 2024 19:30 HKT/SGT
|
|
|
Cropmate Berhad IPO Oversubscribed by 84.88 Times
Nov 27, 2024 18:00 HKT/SGT
|
|
|
Quranium Launches QSafe Wallet with Core Layer (L1) Testnet: The Uncrackable Solution for Blockchain Security
Nov 27, 2024 17:20 HKT/SGT
|
|
|
Survey: New Opportunities in Cross-border E-commerce
Nov 27, 2024 17:11 HKT/SGT
|
|
|
Quranium Node Pre-sale Unveiled: Be Part of the Quantum-Uncrackable Revolution
Nov 27, 2024 17:00 HKT/SGT
|
|
|
Q2 Metals Significantly Expands the Cisco Lithium Property in James Bay, Quebec, Canada
Nov 27, 2024 16:30 HKT/SGT
|
|
|
SF Holding successfully listed in Hong Kong
Nov 27, 2024 16:19 HKT/SGT
|
|
|
Ching Lee Holdings (3728.HK) Reports Significant Growth in Interim Results for 2024
Nov 27, 2024 10:32 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
